A 2016 review cataloged all the peptide receptors on insulin-producing cells that could be targeted for diabetes, presciently highlighting the dual and triple agonist strategy that would later produce tirzepatide and retatrutide.
9+ peptide GPCRs targetable on beta cellsBeyond GLP-1, pancreatic beta cells express receptors for GIP, glucagon, somatostatin, CCK, PYY, and more — enabling the multi-agonist strategy behind today's most effective metabolic drugs.
What the researchers found
This review maps out the landscape of peptide receptors on pancreatic beta cells that can be targeted for diabetes treatment. Beyond the well-known GLP-1 receptor, it covers GIP, glucagon, somatostatin, pancreatic polypeptide, CCK, PYY, oxyntomodulin, and ghrelin receptors — all G-protein coupled receptors (GPCRs) that regulate insulin secretion and metabolism.
Critically, the review highlights the emerging strategy of dual and triple agonist peptides that activate two or more of these receptors simultaneously. It also covers fatty acid GPCRs (GPR40, GPR41, GPR43, GPR84, GPR119, GPR120) that regulate peptide hormone secretion and represent additional drug targets.
Why it matters
This 2016 review was remarkably prescient — the dual and triple agonist approach it described would go on to produce tirzepatide (GLP-1/GIP dual agonist, approved 2022) and retatrutide (GLP-1/GIP/glucagon triple agonist, in Phase 3 trials). Understanding the full map of peptide GPCRs on beta cells explains why multi-targeting approaches are more effective than single-receptor drugs for metabolic disease.
The numbers in context
9+ peptide GPCRs on beta cells · 6 fatty acid GPCRs · Dual and triple agonist approaches · GLP-1, GIP, glucagon, somatostatin, PP, CCK, PYY, OXM, ghrelin receptors
How the study worked
Narrative review of the current state of peptide GPCR drug development for type 2 diabetes, covering receptor biology, existing agonists, and emerging multi-agonist peptide strategies. Includes both preclinical and clinical evidence.
Who was studied
Review covering preclinical and clinical research targeting peptide GPCRs for type 2 diabetes treatment
What this study cannot tell us
Published in 2016, so it predates the clinical validation of many concepts it describes (e.g., tirzepatide's Phase 3 success). As a narrative review, it summarizes rather than systematically evaluates the evidence. Some receptor targets discussed remain preclinical.
How to read the evidence
This is a narrative review summarizing the state of GPCR drug development as of 2016. It synthesizes preclinical and clinical evidence across many receptor targets but does not present original data or use systematic review methodology.
When this study was published
Published in 2016 — before tirzepatide's clinical success validated the dual agonist concept. While some specific trial details are outdated, the receptor biology and multi-agonist framework described remain foundational to current metabolic drug development.
The bigger picture
This review captured a pivotal moment in metabolic drug development — the shift from single-target GLP-1 drugs to multi-receptor peptide agonists. The landscape it described has since exploded: tirzepatide became a blockbuster dual agonist, and triple agonists like retatrutide and survodutide are in advanced trials. The fatty acid GPCR targets it discussed also remain active research areas.
Questions still open
- Is there an upper limit to how many receptors a single peptide can effectively target without unacceptable side effects?
- Which combination of the 9+ peptide GPCRs produces the best metabolic outcomes with the fewest adverse effects?
- Can fatty acid GPCR agonists complement peptide receptor agonists for enhanced metabolic control?
Common questions
What are peptide GPCRs and why do they matter for diabetes treatment?
What are dual and triple agonist peptides?
Read the original research
Development of novel ligands for peptide GPCRs.
Current opinion in pharmacology, 31, 57-62
Citation
Moran, Brian M; McKillop, Aine M; O'Harte, Finbarr Pm. (2016). Development of novel ligands for peptide GPCRs.. Current opinion in pharmacology, 31, 57-62. https://doi.org/10.1016/j.coph.2016.08.009